61 related articles for article (PubMed ID: 38698894)
1. Genomic investigation and clinical correlates of the
Petersiel N; Giulieri S; Daniel DS; Fan S-H; Ersoy SC; Davis JS; Bayer AS; Howden BP; Tong SYC;
Antimicrob Agents Chemother; 2024 Jun; ():e0021824. PubMed ID: 38837393
[TBL] [Abstract][Full Text] [Related]
2. The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia.
McConeghy KW; Bleasdale SC; Rodvold KA
Clin Infect Dis; 2013 Dec; 57(12):1760-5. PubMed ID: 23985343
[TBL] [Abstract][Full Text] [Related]
3. Ceftaroline for the treatment of methicillin-resistant
White BP; Barber KE; Stover KR
Am J Health Syst Pharm; 2017 Feb; 74(4):201-208. PubMed ID: 28179245
[TBL] [Abstract][Full Text] [Related]
4. Combination of Antistaphylococcal β-Lactam With Standard Therapy Compared to Standard Therapy Alone for the Treatment of Methicillin-Resistant
Petersiel N; Davis JS; Meagher N; Price DJ; Tong SYC;
Open Forum Infect Dis; 2024 May; 11(5):ofae181. PubMed ID: 38698894
[TBL] [Abstract][Full Text] [Related]
5. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.
Tong SYC; Lye DC; Yahav D; Sud A; Robinson JO; Nelson J; Archuleta S; Roberts MA; Cass A; Paterson DL; Foo H; Paul M; Guy SD; Tramontana AR; Walls GB; McBride S; Bak N; Ghosh N; Rogers BA; Ralph AP; Davies J; Ferguson PE; Dotel R; McKew GL; Gray TJ; Holmes NE; Smith S; Warner MS; Kalimuddin S; Young BE; Runnegar N; Andresen DN; Anagnostou NA; Johnson SA; Chatfield MD; Cheng AC; Fowler VG; Howden BP; Meagher N; Price DJ; van Hal SJ; O'Sullivan MVN; Davis JS;
JAMA; 2020 Feb; 323(6):527-537. PubMed ID: 32044943
[TBL] [Abstract][Full Text] [Related]
6. Combination of Vancomycin and β-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial.
Davis JS; Sud A; O'Sullivan MVN; Robinson JO; Ferguson PE; Foo H; van Hal SJ; Ralph AP; Howden BP; Binks PM; Kirby A; Tong SYC; ; ; Tong S; Davis J; Binks P; Majumdar S; Ralph A; Baird R; Gordon C; Jeremiah C; Leung G; Brischetto A; Crowe A; Dakh F; Whykes K; Kirkwood M; Sud A; Menon M; Somerville L; Subedi S; Owen S; O'Sullivan M; Liu E; Zhou F; Robinson O; Coombs G; Ferguson P; Ralph A; Liu E; Pollet S; Van Hal S; Foo H; Van Hal S; Davis R
Clin Infect Dis; 2016 Jan; 62(2):173-180. PubMed ID: 26349552
[TBL] [Abstract][Full Text] [Related]
7. Early Administration of Adjuvant β-Lactam Therapy in Combination with Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: A Retrospective, Multicenter Analysis.
Casapao AM; Jacobs DM; Bowers DR; Beyda ND; Dilworth TJ;
Pharmacotherapy; 2017 Nov; 37(11):1347-1356. PubMed ID: 28949410
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin or Daptomycin Plus a β-Lactam Versus Vancomycin or Daptomycin Alone for Methicillin-Resistant
Yi YH; Wang JL; Yin WJ; Xu WH
Microb Drug Resist; 2021 Aug; 27(8):1044-1056. PubMed ID: 33728980
[No Abstract] [Full Text] [Related]
9. Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection.
Doernberg SB; Tran TTT; Tong SYC; Paul M; Yahav D; Davis JS; Leibovici L; Boucher HW; Corey GR; Cosgrove SE; Chambers HF; Fowler VG; Evans SR; Holland TL;
Clin Infect Dis; 2019 May; 68(10):1691-1698. PubMed ID: 30321315
[TBL] [Abstract][Full Text] [Related]
10. Win Ratio Analyses of Piperacillin-Tazobactam Versus Meropenem for Ceftriaxone-Nonsusceptible Escherichia coli or Klebsiella pneumoniae Bloodstream Infections: Post Hoc Insights From the MERINO Trial.
Hardy M; Harris PNA; Paterson DL; Chatfield MD; Mo Y;
Clin Infect Dis; 2024 Jun; 78(6):1482-1489. PubMed ID: 38306577
[TBL] [Abstract][Full Text] [Related]
11. Unlocking the DOOR-how to design, apply, analyse, and interpret desirability of outcome ranking endpoints in infectious diseases clinical trials.
Ong SWX; Petersiel N; Loewenthal MR; Daneman N; Tong SYC; Davis JS
Clin Microbiol Infect; 2023 Aug; 29(8):1024-1030. PubMed ID: 37179006
[TBL] [Abstract][Full Text] [Related]
12. The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe.
Tong SYC; Mora J; Bowen AC; Cheng MP; Daneman N; Goodman AL; Heriot GS; Lee TC; Lewis RJ; Lye DC; Mahar RK; Marsh J; McGlothlin A; McQuilten Z; Morpeth SC; Paterson DL; Price DJ; Roberts JA; Robinson JO; van Hal SJ; Walls G; Webb SA; Whiteway L; Yahav D; Davis JS;
Clin Infect Dis; 2022 Nov; 75(11):2027-2034. PubMed ID: 35717634
[TBL] [Abstract][Full Text] [Related]
13. A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection.
Howard-Anderson J; Dai W; Yahav D; Hamasaki T; Turjeman A; Koppel F; Franceschini E; Hill C; Sund Z; Chambers HF; Fowler VG; Boucher HW; Evans SR; Paul M; Holland TL; Doernberg SB
Open Forum Infect Dis; 2022 Jun; 9(6):ofac140. PubMed ID: 35615299
[TBL] [Abstract][Full Text] [Related]
14. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Turner NA; Zaharoff S; King H; Evans S; Hamasaki T; Lodise T; Ghazaryan V; Beresnev T; Riccobene T; Patel R; Doernberg SB; Rappo U; Fowler VG; Holland TL;
Trials; 2022 May; 23(1):407. PubMed ID: 35578360
[TBL] [Abstract][Full Text] [Related]
15. Immunoguided Discontinuation of Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients Treated With Antithymocyte Globulin: A Randomized Clinical Trial.
Páez-Vega A; Gutiérrez-Gutiérrez B; Agüera ML; Facundo C; Redondo-Pachón D; Suñer M; López-Oliva MO; Yuste JR; Montejo M; Galeano-Álvarez C; Ruiz-San Millan JC; Los-Arcos I; Hernández D; Fernández-Ruiz M; Muñoz P; Valle-Arroyo J; Cano A; Rodríguez-Benot A; Crespo M; Rodelo-Haad C; Lobo-Acosta MA; Garrido-Gracia JC; Vidal E; Guirado L; Cantisán S; Torre-Cisneros J;
Clin Infect Dis; 2022 Mar; 74(5):757-765. PubMed ID: 34228099
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
